Finding the Right CDMO Partner for Tech Transfer

By Emergent CDMO on Nov 18, 2021 4:32:34 PM

Regardless of where a drug candidate is in the development pipeline, performing a technology transfer (tech transfer) presents unique challenges for the partners involved.

Overcoming these challenges is critical to ensuring the ultimate success of the product when working with a Contract Development and Manufacturing Organization (CDMO). There are a myriad of ways in which a tech transfer can fail to meet its potential – unsatisfactory yields, unforeseen materials shortages, unoptimized batch sizes that can impact the quality and timelines of the transferred product.

Topics: Drug Product Fill/Finish White Papers

Utilizing Expertise & Experience for Successful Downstream Processing

By Emergent CDMO on Aug 30, 2021 11:53:37 AM

Successful downstream processing provides isolation of the molecule of interest from extraneous constituents before formulation, allowing for favorable processing of the desired therapeutic or vaccine.

CDMOs that have the expertise and experience in optimizing downstream purification, filtration, and viral clearance processes for diverse and complex molecules can help their clients achieve positive processing outcomes.

Download our white paper to learn more about downstream processing methodologies and techniques, and how Emergent CDMO's vast expertise and experience can help you achieve your drug substance program goals.

DOWNLOAD WHITE PAPER

Topics: White Papers Drug Substance Bioprocessing

Benefits of RABS and Isolator Technology in a Changing Regulatory Landscape

By Emergent CDMO on Aug 19, 2021 2:19:21 PM

Mitigating risk is a key consideration for biopharmaceutical companies when planning their clinical trial material and/or drug product manufacturing processes. One of the most prevalent sources is material handling: every step in the drug substance or drug product manufacturing process can introduce risk.

Biopharma innovators and contract development and manufacturing organizations (CDMOs) collaborate to ensure a number of technologies are utilized to safeguard the integrity of these products. One method is to leverage a Restricted Access Barrier System (RABS) or isolator technology during drug product manufacturing.

Download our white paper to learn more about RABS and isolator technologies, similarities, differences, and benefits, and how Emergent CDMO's vast expertise and experience can help support your drug product manufacturing and packaging needs.

DOWNLOAD WHITE PAPER

Topics: Drug Product Fill/Finish White Papers

Featured